Faculty of Medicine & Dentistry, University of Alberta

Advancing The Edmonton Protocol For The Improved Treatment Of Type 1 Diabetes

Article
Surgical Procedures
Laboratory Procedures
+2
Contributed byMaulik P. Purohit MD MPHJan 08, 2016

An antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of cell transplant treatments for diabetes patients--a procedure that transplants insulin producing islets to render them insulin independent for periods of time.

Anti-aging Glycopeptide (AAGP™) is the focus of a new study published in the journal Diabetes. Researchers from the University of Alberta's Faculty of Medicine & Dentistry found that by soaking islet cells in AAGP™ for an hour and then washing it off prior to transplantation, the cells were protected from tacrolimus--an antirejection drug commonly used during transplants that is toxic to islets cells.

"Normally when we expose human islets to tacrolimus in the petri dish, they flat line and don't release insulin at all," says James Shapiro, senior author of the study and Canada Research Chair in Transplant Surgery and Regenerative Medicine at the U of A. "When we add the AAGP™ and wash it all off, the cells work perfectly normally, and are protected in a remarkably durable manner. We find we need far fewer cells to treat diabetes in our preclinical models than we would normally."

Since his creation of the Edmonton Protocol in 1999, more than 250 patients have been treated by Shapiro through islet cell transplantation. A key challenge of the procedure though is that most patients typically need two islet infusions, each prepared from a separate pancreas organ donor. Shapiro says there aren't enough organ donors to meet demand. Through the use AAGP™, a greater number of islet cells will survive the procedure, potentially allowing more patients to be treated.

"Just a one-hour soak in AAGP™ is enough to protect the islet cells for up to a month or two afterwards. It has a very potent and profound effect," says Shapiro. "As a direct result of these findings, we're now moving forward with plans for a first in human clinical trial--led at the University of Alberta--testing this drug in our human islet cell transplant program."

"This synthetic molecule seems to provide significant protection to cells exposed to multiple deleterious conditions, such as UV radiation, starvation, extreme temperatures andoxidative stress," says Boris Gala-Lopez, lead author of the study and a clinical/research fellow at the U of A's Department of Surgery. "We are certainly very excited for the multiple opportunities this finding entails to the field of transplantation research."

Funding for the study was provided by the Diabetes Research Institute Foundation of Canada, while the drug AAGP™ was provided in kind by Protokinetix--a biotechnology company that provides medical researchers assistance in enhancing cell survival and health.

"We are very excited to have our AAGP™ molecule showcased in this journal. We are also extremely confident in the ongoing success of our collaboration with Dr. James Shapiro and his outstanding team," says Clarence Smith, president and chairman of ProtoKinetix.

If proven successful in human clinical trials, Shapiro believes the inclusion of AAGP™ could soon become a permanent addition to the Edmonton Protocol--representing a significant step forward in the treatment of Type 1 diabetes through islet transplantation. While more research is needed, he also believes the drug shows promise for a wide range of transplantations--potentially working to protect organs as effectively as it protects islets.


The above post is reprinted from materials provided by University of Alberta Faculty of Medicine & Dentistry. The original item was written by Ross Neitz. Note: Materials may be edited for content and length.

Disclaimer: DoveMed is not responsible for the adapted accuracy of news releases posted to DoveMed by contributing universities and institutions.

Primary Resource:

Gala-Lopez, B. L., Pepper, A. R., Pawlick, R. L., O’Gorman, D., Kin, T., Bruni, A., ... & Young, L. G. (2015). Anti-aging Glycopeptide Protects Human Islets Against Tacrolimus-related Injury and Facilitates Engraftment in Mice.Diabetes, db150764.

Was this article helpful

On the Article

Maulik P. Purohit MD MPH picture
Approved by

Maulik P. Purohit MD MPH

Assistant Medical Director, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!